Multi-country surveillance of paediatric invasive group A Streptococcus infection, European Union/European Economic Area countries, 2022/23 season

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F25%3A00015123" target="_blank" >RIV/75010330:_____/25:00015123 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/25:43928981

Výsledek na webu

<a href="https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.42.2500079" target="_blank" >https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.42.2500079</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2807/1560-7917.ES.2025.30.42.2500079" target="_blank" >10.2807/1560-7917.ES.2025.30.42.2500079</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Multi-country surveillance of paediatric invasive group A Streptococcus infection, European Union/European Economic Area countries, 2022/23 season

Popis výsledku v původním jazyce

Background: Group A Streptococcus (GAS) commonly causes mild bacterial infections but also deadly invasive disease. An upsurge in paediatric invasive GAS (iGAS) infections was observed during the last quarter of 2022 in the European Union/European Economic Area (EU/EEA) countries. Aim: We aimed to assess iGAS surveillance in the EU/EEA countries and investigate the epidemiology of iGAS infections during the 2022/23 season. Methods: We conducted a study on GAS and iGAS surveillance to evaluate coverage and surveillance methodology across the EU/ EEA countries. We collected and analysed data on paediatric iGAS cases (patients aged <= 16 years) occurring in September 2022-June 2023 that resulted in hospitalisation or death. Associations of severe outcome (admission to intensive care unit and/or death) with potential risk factors were estimated by logistic regression in a case-case analysis. Results: Nineteen countries responded to the questionnaire; eleven had mandated national surveillance for iGAS before 2022. Eight countries submitted data on 1,277 paediatric iGAS cases involving hospitalisation or death: 56% were males and median age was 4 years. Sixtythree (5%) of these cases died. Severe outcome was associated with emm1 type (odds ratio (OR) = 1.73; 95% confidence interval (CI): 1.13-2.67), having a sepsis without a known anatomic source (OR = 1.73; 95% CI: 1.11-2.73) and lower respiratory tract infections (OR = 4.14; 95% CI: 2.70-6.44). Conclusion: Surveillance of GAS and iGAS infections varied among the participating countries. We highlight the importance of including emm typing and analysis of clinical data in iGAS surveillance and having international collaboration for effective response to future surges.

Název v anglickém jazyce

Multi-country surveillance of paediatric invasive group A Streptococcus infection, European Union/European Economic Area countries, 2022/23 season

Popis výsledku anglicky

Background: Group A Streptococcus (GAS) commonly causes mild bacterial infections but also deadly invasive disease. An upsurge in paediatric invasive GAS (iGAS) infections was observed during the last quarter of 2022 in the European Union/European Economic Area (EU/EEA) countries. Aim: We aimed to assess iGAS surveillance in the EU/EEA countries and investigate the epidemiology of iGAS infections during the 2022/23 season. Methods: We conducted a study on GAS and iGAS surveillance to evaluate coverage and surveillance methodology across the EU/ EEA countries. We collected and analysed data on paediatric iGAS cases (patients aged <= 16 years) occurring in September 2022-June 2023 that resulted in hospitalisation or death. Associations of severe outcome (admission to intensive care unit and/or death) with potential risk factors were estimated by logistic regression in a case-case analysis. Results: Nineteen countries responded to the questionnaire; eleven had mandated national surveillance for iGAS before 2022. Eight countries submitted data on 1,277 paediatric iGAS cases involving hospitalisation or death: 56% were males and median age was 4 years. Sixtythree (5%) of these cases died. Severe outcome was associated with emm1 type (odds ratio (OR) = 1.73; 95% confidence interval (CI): 1.13-2.67), having a sepsis without a known anatomic source (OR = 1.73; 95% CI: 1.11-2.73) and lower respiratory tract infections (OR = 4.14; 95% CI: 2.70-6.44). Conclusion: Surveillance of GAS and iGAS infections varied among the participating countries. We highlight the importance of including emm typing and analysis of clinical data in iGAS surveillance and having international collaboration for effective response to future surges.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Euro Surveillance

ISSN

1025-496X

e-ISSN

1560-7917

Svazek periodika

30

Číslo periodika v rámci svazku

42

Stát vydavatele periodika

SE - Švédské království

Počet stran výsledku

14

Strana od-do

2500079

Kód UT WoS článku

001613804600002

EID výsledku v databázi Scopus

2-s2.0-105019822701